Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHLORZOXAZONE vs SEIZALAM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion conductance and neuronal hyperpolarization.
Adjunct for relief of acute painful musculoskeletal conditions associated with muscle spasm
Status epilepticus,Acute repetitive seizures,Seizure clusters
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
0.5 mg orally twice daily, titrated weekly by 0.5 mg/day to a maximum of 4 mg/day
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
Terminal elimination half-life is 15–20 hours in adults; prolonged in elderly and hepatic impairment (up to 40 hours).
Hepatic, primarily via CYP2E1, also CYP1A2 and CYP3A4
Hepatic via CYP3A4 and glucuronidation; active metabolite N-desmethylclobazam.
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine. Metabolites are excreted renally (approx. 70%) and fecal/biliary (approx. 30%).
Approximately 90–95% bound, primarily to albumin.
Approximately 98% bound to albumin.
0.46–0.64 L/kg; indicates distribution into total body water.
1.0–1.5 L/kg; reflects extensive tissue distribution.
Oral: nearly complete; rapidly absorbed with extensive first-pass metabolism; systemic bioavailability approximately 30–50% due to first-pass effect.
Oral: 70–90%; Intramuscular: 80–95% (relative to IV).
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of active metabolite.
GFR 30-89 m L/min: no adjustment; GFR <30 m L/min: reduce dose by 50%; hemodialysis: 0.25 mg daily
Contraindicated in hepatic impairment; avoid use in Child-Pugh class B or C due to risk of hepatotoxicity.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated
Not established; safety and efficacy not studied in pediatric patients.
0.01 mg/kg/dose (up to 0.5 mg) twice daily, titrate weekly to max 0.1 mg/kg/day (not to exceed adult max)
Initiate at lower end of dosing range (250 mg 3-4 times daily); monitor for CNS effects (dizziness, drowsiness) and liver function.
0.25 mg once daily initially; titrate slowly to 0.5 mg twice daily; max 2 mg/day
None
Risk of respiratory depression, hypotension, and cardiac arrest; coadministration with CNS depressants increases risk.
May cause drowsiness, dizziness, or impaired coordination. Caution in patients with hepatic impairment. Discontinue if hypersensitivity reactions occur. Avoid concurrent use with alcohol or other CNS depressants.
Respiratory depression, hypotension, sedation, tolerance, withdrawal seizures, abuse potential, paradoxical reactions.
Hypersensitivity to chlorzoxazone or any component of the formulation; impaired hepatic function
Hypersensitivity to benzodiazepines, severe respiratory insufficiency, myasthenia gravis, narrow-angle glaucoma.
No significant food interactions. Take with or without food. Grapefruit juice may increase drug levels; avoid large quantities.
Grapefruit and grapefruit juice may increase midazolam levels; avoid concurrent use. High-fat meals may reduce absorption of oral formulation; administer on empty stomach if possible.
Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if clearly needed and after weighing risks vs. benefits. Avoid during first trimester unless necessary.
First trimester: Increased risk of major congenital malformations, particularly neural tube defects and orofacial clefts (OR 2.0-3.0). Second/third trimester: Fetal growth restriction, preterm birth, neurodevelopmental deficits. Chronic use: Neonatal withdrawal syndrome, floppy infant syndrome.
Not recommended during breastfeeding due to potential for sedation in the infant. No M/P ratio data available.
M/P ratio 0.8; excreted into breast milk; levels low (0.1-0.5 mg/L). Monitor infant for sedation, poor feeding, weight loss. Caution recommended; alternative therapy if infant shows adverse effects.
No dosage adjustment specific to pregnancy is required based on pharmacokinetic data; however, clinical response should be monitored.
Increased clearance and volume of distribution in pregnancy; dose increase of 30-50% often required to maintain therapeutic levels. Monitor trough concentrations and adjust as needed, especially in third trimester.
Chlorzoxazone is a centrally acting muscle relaxant used for acute musculoskeletal pain. Onset of action is within 1 hour; peak effect at 1-2 hours. Monitor for hepatotoxicity, especially with prolonged use or high doses. Can cause drowsiness and impair motor skills; avoid concurrent use with alcohol or other CNS depressants. Tablets may be crushed for patients with swallowing difficulties.
SEIZALAM (midazolam) is a short-acting benzodiazepine used for acute seizure control. Administer IV/IM; intranasal formulation available. Onset within 2-5 minutes. Monitor respiratory depression, especially with concurrent opioids. Flumazenil is reversal agent. Avoid in narrow-angle glaucoma. Dose adjust in elderly and hepatic impairment.
Take exactly as prescribed; do not increase dose or frequency.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Report signs of liver problems: dark urine, yellowing of eyes/skin, persistent nausea, abdominal pain.,Do not suddenly stop taking if used long-term; taper under medical supervision to avoid withdrawal.
Take exactly as prescribed; do not stop abruptly to avoid withdrawal seizures.,May cause drowsiness, dizziness; avoid driving or operating machinery.,Avoid alcohol and other CNS depressants.,Report any difficulty breathing, severe sedation, or rash immediately.,Store at room temperature away from light and moisture.
"Lumacaftor is a strong inducer of cytochrome P450 (CYP) 3A4 and other drug-metabolizing enzymes, including CYP2E1. Chlorzoxazone is primarily metabolized by CYP2E1 to its inactive metabolite. Concomitant use increases CYP2E1 activity, leading to accelerated chlorzoxazone clearance and reduced systemic exposure, potentially diminishing its therapeutic effect as a muscle relaxant."
"Chlorzoxazone, a centrally acting muscle relaxant, inhibits the metabolism of diltiazem, a calcium channel blocker, via competitive inhibition of CYP3A4. This leads to increased plasma concentrations of diltiazem, potentially causing enhanced negative chronotropic and vasodilatory effects, resulting in bradycardia, hypotension, or atrioventricular block. Patients may experience dizziness, syncope, or exacerbate heart failure symptoms."
"Butalbital, a barbiturate, induces hepatic cytochrome P450 enzymes (particularly CYP2E1), accelerating the metabolism of chlorzoxazone, a centrally acting muscle relaxant primarily metabolized by CYP2E1. This results in reduced plasma concentrations of chlorzoxazone, leading to diminished therapeutic efficacy and potential loss of symptom control. Clinically, patients may experience inadequate muscle relaxation, requiring dose adjustments or alternative therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHLORZOXAZONE vs SEIZALAM, answered by our medical review team.
CHLORZOXAZONE is a Skeletal Muscle Relaxant that works by Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.. SEIZALAM is a Benzodiazepine Anticonvulsant that works by Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion conductance and neuronal hyperpolarization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHLORZOXAZONE and SEIZALAM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHLORZOXAZONE is: 250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.. The standard adult dose of SEIZALAM is: 0.5 mg orally twice daily, titrated weekly by 0.5 mg/day to a maximum of 4 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHLORZOXAZONE and SEIZALAM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHLORZOXAZONE is classified as Category C. Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if cl. SEIZALAM is classified as Category C. First trimester: Increased risk of major congenital malformations, particularly neural tube defects and orofacial clefts (OR 2.0-3.0). Second/third trimester: Fetal growth restrict. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.